In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells
- PMID: 9049043
- DOI: 10.1007/s004030050161
In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells
Abstract
The long-term use of immunosuppressive agents may cause profound suppression of the cutaneous immune function. Because epidermal Langerhans cells (LC) play an important role in the cutaneous immune system, they could be the target of immunosuppressants. Since little information is available about the direct immunosuppressive effects of methotrexate (MTX) and azathioprine (AZA) on LC, we studied the viability and immunostimulatory effects of purified LC after pulsation with MTX or AZA at various concentrations. Both MTX and AZA started to suppress the mixed LC-T lymphocyte reaction (MLCLR) significantly at a concentration of 1 microgram/ml. However, the suppressive effect of MTX was not dose-dependent; no further suppression was seen up to a concentration of 1 mg/ml. MTX showed no inhibitory effect on the viability of LC even at concentrations as high as 1 mg/ml. In contrast, the suppressive effect of AZA on the MLCLR was dose-dependent and AZA at a concentration of 500 micrograms/ml or higher markedly decreased the viability of LC. Our study confirmed the immunosuppressive effect of MTX and AZA on epidermal LC. In comparison to MTX, AZA at pharmacological levels showed stronger inhibitory effects on alloantigen-presenting capacity of human epidermal LC and was more cytotoxic to LC. In the therapeutic range, however, MTX and AZA probably have no direct effect on epidermal LC. Our study supports the notion that long-term immunosuppressants deplete cutaneous LC by bone marrow suppression.
Similar articles
-
Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review.Eur J Paediatr Neurol. 2019 Jan;23(1):7-18. doi: 10.1016/j.ejpn.2018.09.008. Epub 2018 Sep 27. Eur J Paediatr Neurol. 2019. PMID: 30318435
-
Reduction in murine Langerhans cell ATPase staining following topical but not systemic treatment with steroid and non-steroid immunosuppressants.Br J Dermatol. 1986 Jan;114(1):83-9. doi: 10.1111/j.1365-2133.1986.tb02782.x. Br J Dermatol. 1986. PMID: 2935180
-
The effect of methotrexate and azathioprine on the serum levels of IgA-alpha 1-antitrypsin complex in juvenile chronic arthritis.Braz J Med Biol Res. 1997 Jun;30(6):763-7. doi: 10.1590/s0100-879x1997000600010. Braz J Med Biol Res. 1997. PMID: 9292114
-
Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis.Eur J Med Res. 1999 Oct 15;4(10):442-8. Eur J Med Res. 1999. PMID: 10527958
-
Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.Arthritis Rheum. 1996 Jun;39(6):1016-20. doi: 10.1002/art.1780390619. Arthritis Rheum. 1996. PMID: 8651964 Review.
Cited by
-
Long term treatment concepts and proactive therapy for atopic eczema.Ann Dermatol. 2012 Aug;24(3):253-60. doi: 10.5021/ad.2012.24.3.253. Epub 2012 Jul 25. Ann Dermatol. 2012. PMID: 22879707 Free PMC article.
-
Systemic therapy of atopic dermatitis.Allergol Select. 2017 Aug 4;1(1):1-8. doi: 10.5414/ALX01285E. eCollection 2017. Allergol Select. 2017. PMID: 30402595 Free PMC article.
-
Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology.Postepy Dermatol Alergol. 2015 Aug;32(4):239-49. doi: 10.5114/pdia.2015.53319. Epub 2015 Aug 12. Postepy Dermatol Alergol. 2015. PMID: 26366146 Free PMC article.